Eli Lilly is trading 3% down at $1146.36 after CVS Health’s pharmacy benefits arm raised concerns over the return on investment for expensive GLP-1 weight-loss drugs.
- CVS Health’s pharmacy benefits manager warned that broad coverage for therapies like Zepbound lacks a proven ROI at current high monthly price points.
- The comments have pressured investor sentiment regarding future reimbursement levels and sustained demand for high-cost obesity treatments.